Zymeworks (NASDAQ:ZYME) Upgraded to “Hold” at Wells Fargo & Company

Zymeworks (NASDAQ:ZYME) was upgraded by analysts at Wells Fargo & Company to a “hold” rating in a note issued to investors on Friday,Zacks.com reports.

ZYME has been the topic of several other research reports. HC Wainwright upgraded Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Wall Street Zen cut Zymeworks from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 19th. B. Riley upgraded Zymeworks to a “strong-buy” rating in a research note on Thursday, October 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Zymeworks currently has a consensus rating of “Moderate Buy”.

Zymeworks Stock Performance

Shares of ZYME opened at $17.74 on Friday. The stock’s 50-day moving average is $16.18. The firm has a market capitalization of $1.33 billion, a PE ratio of -18.29 and a beta of 1.51. Zymeworks has a 12 month low of $9.03 and a 12 month high of $19.50.

Zymeworks (NASDAQ:ZYME) last released its quarterly earnings results on Tuesday, November 8th. The company reported ($1.14) EPS for the quarter. Zymeworks had a negative return on equity of 21.59% and a negative net margin of 59.96%.The business had revenue of $4.40 million during the quarter.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.